EC
BHVN icon

EcoR1 Capital’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

EcoR1 Capital’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-70,000
Closed -$1.75M – 52
2017
Q2 		$1.75M Buy
+70,000
New +$1.61M 0.31% 29

Other funds holding BHVN

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EcoR1 Capital's BHVN Position: Q3 2017 in Review

EcoR1 Capital sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2017, closing a stake of 70,000 shares — an estimated $1.75M sold.

EcoR1 Capital first reported a position in BHVN in Q2 2017 and held it in 1 quarter. The position peaked at $1.75M in Q2 2017. 75 funds tracked by Wall St. Rank hold BHVN as of Q3 2017.

  • EcoR1 Capital reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2017 after selling out during the quarter.
  • EcoR1 Capital sold 70,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2017, an estimated $1.75M.
  • EcoR1 Capital first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2017 and held it in 1 quarter.
  • EcoR1 Capital's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.75M in Q2 2017.
  • 75 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2017.

Based on EcoR1 Capital's 13F filing for Q3 2017, filed 14 Nov 2017.